Checkpoint Therapeutics
CompanyUnited States
Checkpoint Therapeutics develops one asset, approved (cosibelimab-ipdl in metastatic cutaneous squamous cell carcinoma). Mostly antibody acting on CD274; based in the United States.
- 1
- Asset
- Furthest stage
- Approved
- Raised
- $57.8M
- 2
- Trials
- 1
- Signal
Pipeline
1Blocks PD-L1 to restore antitumor immune responses.
Approved, Antibody, CD274, metastatic cutaneous squamous cell carcinoma, locally advanced cutaneous squamous cell carcinoma
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials3
- Funding rounds and grants1
- Deals12
- People8
- Signals1
- Similar companies6